In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were presented today at the 2017 San Antonio Breast Cancer...
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...
As an institution dedicated to ending cancer, The University of Texas MD Anderson Cancer Center is committed to promoting cancer prevention...
Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly among older Texas patients with colon cancer since 2001, while adherence to chemotherapy guidelines has remained largely unchanged. The study, published today in Cancer, identifies factors influencing adherence rates, including socioeconomic status and access to skilled physicians.
The researchers...
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used...
The University of Texas MD Anderson Cancer Center celebrates the five-year anniversary of its Moon Shots Program™, a collaborative effort...
Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve...
Sarah Ann Roder, a clinical nurse in the Gynecologic Oncology Outpatient Center at The University of Texas MD Anderson Cancer Center,...
In an effort to improve public health and lower the risk of cancer, Baytown community organizations are partnering with The University of...
Houston philanthropist Rich Kinder, executive chairman of Kinder Morgan Inc., will join Houston-based NBC News correspondent Janet Shamlian...
A targeted therapy resurrected by the Moon Shots Program™ at The University of Texas MD Anderson Cancer Center has produced unprecedented...
Cattlemen for Cancer Research (CCR) will hold its 19th annual auction Saturday, Oct. 21 at the Hills Prairie Livestock Auction Company, 1177...
The University of Texas MD Anderson Cancer Center has opened registration for the second annual Boot Walk to End Cancer®, Saturday, Nov...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge...
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on...
As the official cancer center of the PGA TOUR, The University of Texas MD Anderson Cancer Center will provide complimentary skin cancer screenings...
William Atkinson is the 2017 recipient of the Julie and Ben Rogers Award for Excellence in Administration at The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center this week was awarded $7.5 million from the Cancer Prevention and Research Institute of...
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against...
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell...
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused...
ABSTRACT: 6003
Researchers have found that the human papillomavirus (HPV) vaccine may reduce the rate of oral HPV infections in young...
The University of Texas MD Anderson Cancer Center named eight innovative researchers to the second annual class of Andrew Sabin Family Fellows...
The American Dental Association (ADA) and The University of Texas MD Anderson Cancer Center today announced a joint effort to improve patient...
The University of Texas System convened its 2nd Annual Eliminate Tobacco Use Summit April 17-18 in Austin to enhance tobacco control...
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party...
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and...
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies...
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC),...
As an institution devoted to eliminating cancer, The University of Texas MD Anderson Cancer Center proudly supports the mission of Kick Butts...
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard...
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid...
The University of Texas MD Anderson Cancer Center this week was awarded $19.5 million from the Cancer Prevention and Research Institute of...
Recognizing a critical need to address disparities in cancer care, The University of Texas MD Anderson Cancer Center has been designated as...
The University of Texas MD Anderson Cancer Center fully supports the proposed rule released today by the U.S. Food and Drug Administration...
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known...
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united...
The University of Texas MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and...